E
Eric M. Green
Researcher at Catholic Medical Center
Publications - 32
Citations - 3130
Eric M. Green is an academic researcher from Catholic Medical Center. The author has contributed to research in topics: Hypertrophic cardiomyopathy & Cardiomyopathy. The author has an hindex of 15, co-authored 28 publications receiving 2494 citations. Previous affiliations of Eric M. Green include Stanford University & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Gabapentin Receptor α2δ-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis
Cagla Eroglu,Cagla Eroglu,Nicola J. Allen,Michael W. Susman,Nancy A. O'Rourke,Chan Young Park,Engin Özkan,Chandrani Chakraborty,Sara B. Mulinyawe,Douglas S. Annis,Andrew D. Huberman,Eric M. Green,Jack Lawler,Ricardo E. Dolmetsch,K. Christopher Garcia,Stephen J. Smith,Z. David Luo,Arnon Rosenthal,Deane F. Mosher,Ben A. Barres +19 more
TL;DR: The neuronal thrombospondin receptor involved in CNS synapse formation is identified as alpha2delta-1, the receptor for the anti-epileptic and analgesic drug gabapentin and suggested that gapapentin may function therapeutically by blocking new synapses formation.
Journal ArticleDOI
A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice
Eric M. Green,Hiroko Wakimoto,Robert L. Anderson,Marc J. Evanchik,Joshua M. Gorham,Brooke C. Harrison,Marcus Henze,Raja Kawas,Johan D. Oslob,Hector M. Rodriguez,Yonghong Song,William Wan,Leslie A. Leinwand,James A. Spudich,Robert S. McDowell,Jonathan G. Seidman,Christine E. Seidman,Christine E. Seidman,Christine E. Seidman +18 more
TL;DR: It is demonstrated that early, chronic administration of MYK-461 suppresses the development of ventricular hypertrophy, cardiomyocyte disarray, and myocardial fibrosis and attenuates hypertrophic and profibrotic gene expression in mice harboring heterozygous human mutations in the myosin heavy chain.
Gabapentin Receptor alpha 2 delta-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis
Cagla Eroglu,Nicola J. Allen,Michael W. Susman,Nancy A. O'Rourke,Chan Young Park,Engin Oezkan,Chandrani Chakraborty,Sara B. Mulinyawe,Douglas S. Annis,Andrew D. Huberman,Eric M. Green,Jack Lawler,Ricardo E. Dolmetsch,K. Christopher Garcia,Stephen J. Smith,Z. David Luo,Arnon Rosenthal,Deane F. Mosher,Ben A. Barres +18 more
Journal ArticleDOI
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe)
Carolyn Y. Ho,Sharlene M. Day,Euan A. Ashley,Michelle Michels,Alexandre C. Pereira,Daniel Jacoby,Allison L. Cirino,Jonathan C. Fox,Neal K. Lakdawala,James S. Ware,Colleen Caleshu,Adam S. Helms,Steven D. Colan,Francesca Girolami,Franco Cecchi,Christine E. Seidman,Christine E. Seidman,Gautam Sajeev,James Signorovitch,Eric M. Green,Iacopo Olivotto +20 more
TL;DR: The cumulative burden of HCM is substantial and dominated by heart failure and atrial fibrillation occurring many years after diagnosis, highlighting the need for close surveillance throughout life and the need to develop disease-modifying therapies.
Journal ArticleDOI
Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers
Robert L. Anderson,Darshan V. Trivedi,Saswata S. Sarkar,Marcus Henze,Weikang Ma,Henry Gong,Christopher S. Rogers,Joshua M. Gorham,Fiona L. Wong,Makenna M. Morck,Jonathan G. Seidman,Kathleen M. Ruppel,Thomas C. Irving,Roger Cooke,Eric M. Green,James A. Spudich +15 more
TL;DR: Light is shed on the biochemical and molecular nature of SRX and the mechanism of action of mavacamten, a cardiac inhibitor in phase 2 clinical trials, is demonstrated, which provides a biochemical and structural link between the genetics and physiology of cardiomyopathy with implications for therapeutic strategies.